Deals this week: Integra LifeSciences, CathWorks, Mallinckrodt

6 October 2017 (Last Updated October 19th, 2017 12:30)

Integra LifeSciences Holdings has purchased Johnson and Johnson’s (J&J) Codman Neurosurgery business for $1.045bn.

Integra LifeSciences Holdings has purchased Johnson and Johnson’s (J&J) Codman Neurosurgery business for $1.045bn.

The acquisition will strengthen the US-based surgical and medical instrument manufacturer’s neurosurgical products portfolio.

CathWorks Ltd has secured $15.8m in a series B funding round led by Quark Venture Inc and Triventures.

The Israeli non-invasive FFR measurements developer plans to use the funds to carry out global trials for 510K Food and Drug Administration (FDA) approval.

Mallinckrodt plc has signed a licensing agreement to develop US-based pharmaceutical company NeuroproteXeon Inc’s pharmaceutical-grade xenon gas inhalation therapy.

“The Canadian robotic solutions designer will use the funds to develop innovative products and carry out research to improve its production efficiency.”

The UK-based pharmaceutical company will pay $10m towards initial development costs as per the agreement and obtain an exclusive license to market the therapy. It will make additional payments of up to $25m once it has achieved certain clinical and sales milestones.

US-based company AxoGen Inc plans to raise up to $92.24m by issuing four million shares of its common stock priced at $18.98 a share.

Kinova Robotics has raised C$25m ($20m) in funding from four investors, including Fonds Manufacturier, KTB Network, Foxconn, and BDC Capital.

The Canadian robotic solutions designer will use the funds to develop innovative products and carry out research to improve its production efficiency.